Literature DB >> 1681947

Decreased serum dipeptidyl peptidase IV activity in major depression.

M Maes1, I De Meester, G Vanhoof, S Scharpé, E Bosmans, C Vandervorst, R Verkerk, B Minner, E Suy, J Raus.   

Abstract

It has been recently shown that severe depression is characterized by immune dysfunctions such as blunted mitogen-induced blast transformation, which is linked to interleukin-2 (IL-2) mechanisms, and to autoimmune responses. In order to explore one of the putative pathophysiological mechanisms underlying both factors, we have measured the predexamethasone and postdexamethasone serum dipeptidyl-peptidase IV (DPP IV) activity in depressed inpatients and normal controls. This enzyme is an important mediator of IL-2-related blast proliferation, and it may play a role in autoimmunity. We found significantly lower DPP IV levels in major depressives as compared with healthy controls, and melancholics exhibited significantly lower enzyme activity than minor depressives. There was a significant negative correlation between serum DPP IV activity and the severity of illness. However, we were unable to detect any significant relationships between DPP IV on the one hand, and mitogen-induced blast transformation, soluble IL-2 receptor accumulation in PHA culture supernatant, total number of leukocytes and lymphocytes, T lymphocytes, CD4+ and CD25+ cells, on the other. Men exhibited significantly higher serum DPP IV levels than women.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1681947     DOI: 10.1016/0006-3223(91)90027-j

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  5 in total

Review 1.  Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein.

Authors:  Roger Yazbeck; Simone E Jaenisch; Catherine A Abbott
Journal:  Protoplasma       Date:  2017-06-16       Impact factor: 3.356

Review 2.  The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression.

Authors:  Michael Maes; Raz Yirmyia; Jens Noraberg; Stefan Brene; Joe Hibbeln; Giulia Perini; Marta Kubera; Petr Bob; Bernard Lerer; Mario Maj
Journal:  Metab Brain Dis       Date:  2008-12-16       Impact factor: 3.584

Review 3.  Dpp4 inhibition as a therapeutic strategy in cardiometabolic disease: Incretin-dependent and -independent function.

Authors:  Quan Gong; Sanjay Rajagopalan; Jixin Zhong
Journal:  Int J Cardiol       Date:  2015-06-27       Impact factor: 4.164

4.  Towards a possible aetiology for depressions?

Authors:  Ying Liu; Tore Heiberg; Karl-Ludvig Reichelt
Journal:  Behav Brain Funct       Date:  2007-09-14       Impact factor: 3.759

5.  Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink.

Authors:  John-Michael Gamble; Eugene Chibrikov; William K Midodzi; Laurie K Twells; Sumit R Majumdar
Journal:  BMJ Open       Date:  2018-10-08       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.